Most efforts have focused on exploiting CD33 as a target in this disease, and several clinical trials have confirmed the anti-leukemic activity of GO in CD33-positive AML cells and have demonstrated improved outcomes in AML patients. Here, CD33 is linked to acute myeloid leukemia.